Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

Inclusion Criteria: * Adult volunteers to be vaccinated with the ComirnatyTM vaccine and to participate in the study, belonging to one of the following groups: * Group of immunocompromised (15 participants per immunosuppression subgroup): * Kidney transplant * Extracorporeal dialysis * Solid cancer under chemotherapy and / or radiotherapy * Myeloma under chemotherapy * Hematologic malignancies under chemotherapy * Diseases treated with anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after) * Multiple sclerosis under anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after) * Common variable immune deficiency or other causes of severe hypogammaglobulinemia requiring chronic treatment with polyvalent immunoglobulin * Malignant tumor under anti-PD1 or anti-PDL1 * People living with HIV * Complicated type 2 diabetes (with micro and / or macroangiopathy) * Group of non-immunocompromised subjects (controls, n = 75) * 60 people vaccinated with the ComirnatyTM * 15 people vaccinated with Astra Zeneca's VaxzevriaTM for the first dose Exclusion Criteria: * Minors * Pregnant or breastfeeding women * Persons under tutorship or curatorship * Protected adults * Person under legal protection * Person not affiliated to a social security scheme * People with a contraindication to receiving the ComirnatyTM vaccine * People who have already been vaccinat…